Tenecteplase biosimilar is under clinical development by Generium and currently in Phase III for Myocardial Infarction. According to GlobalData, Phase III drugs for Myocardial Infarction have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Tenecteplase biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tenecteplase biosimilar overview
Tenecteplase biosimilar (GNR-060) is under development for the treatment of myocardial infarction. It is administered through intravenous bolus route.
See Also:
Generium overview
Generium is a pharmaceutical company developing novel biological drugs for the treatment of orphan diseases. Generium is headquartered in Moscow, Russia.
For a complete picture of Tenecteplase biosimilar’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.